Alto Neuroscience ANRO
NYSE ANRO
$35.56 -0.84 (-2.31%)
As of: Sep 4, 2026 · 3:59 PM EDT

Alto Neuroscience (ANRO) Other Non-Current Liabilities (2023)

Alto Neuroscience (ANRO) posted Other Non-Current Liabilities of $1.4 million for Q4 2023, down 3.43% sequentially from $1.4 million in Q3 2023.

Analysis

Alto Neuroscience (ANRO) Other Non-Current Liabilities (2023) Analysis & Trends

Alto Neuroscience has reported Other Non-Current Liabilities for 1 years, with the latest figure at $1.4 million in Q4 2023.

  • Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.4 million (changed N/A YoY) and the FY2023 annual result came in at $1.4 million, changed N/A from the prior year.
  • Other Non-Current Liabilities declined to $1.4 million in Q4 2023 per ANRO's latest filing, from $1.4 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $1.7 million in Q1 2023 and troughed at $1.4 million in Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Alto Neuroscience 1.52 Bn 1.52 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 1.35 Mn
Sep 30, 2023 1.40 Mn
Jun 30, 2023 1.60 Mn
Mar 31, 2023 1.70 Mn